Published in Br J Pharmacol on May 01, 2012
The serotonin syndrome. N Engl J Med (2005) 8.98
Neurotransmitter transporters: recent progress. Annu Rev Neurosci (1993) 3.80
Methylene blue for rapid identification of the parathyroids. Br Med J (1971) 2.89
Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol (1993) 2.35
Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol (2000) 2.24
Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol (2007) 1.81
Prolonged postoperative disorientation after methylene blue infusion during parathyroidectomy. Anesth Analg (2004) 1.72
Nitric oxide and the vascular endothelium. Handb Exp Pharmacol (2006) 1.70
The role of methylene blue in serotonin syndrome: a systematic review. Psychosomatics (2010) 1.68
Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J Biol Chem (2000) 1.60
Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation. Mol Pharmacol (2004) 1.57
Rapid intraoperative localization of parathyroid glands utilizing methylene blue infusion. Otolaryngol Head Neck Surg (2004) 1.54
Methylene Blue--a therapeutic dye for all seasons? J Chemother (2002) 1.43
Physical properties of biological membranes determined by the fluorescence of the calcium ionophore A23187. Arch Biochem Biophys (1974) 1.36
Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J Biol Chem (1998) 1.34
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob Agents Chemother (2007) 1.28
High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol (2008) 1.27
Methylene blue and Alzheimer's disease. Biochem Pharmacol (2009) 1.27
Cellular and molecular actions of Methylene Blue in the nervous system. Med Res Rev (2011) 1.22
Binding and transport in norepinephrine transporters. Real-time, spatially resolved analysis in single cells using a fluorescent substrate. J Biol Chem (2002) 1.21
Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem (2007) 1.19
Adenosine A3 receptors regulate serotonin transport via nitric oxide and cGMP. J Biol Chem (1994) 1.18
Serotonin-transporter mediated efflux: a pharmacological analysis of amphetamines and non-amphetamines. Neuropharmacology (2005) 1.17
The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol (2005) 1.13
Methylene blue implicated in potentially fatal serotonin toxicity. Anaesthesia (2006) 1.11
A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry (1986) 1.08
Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. Psychopharmacology (Berl) (2008) 1.02
Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos (1996) 0.97
A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry (1987) 0.97
Rapid stimulation of presynaptic serotonin transport by A(3) adenosine receptors. J Pharmacol Exp Ther (2007) 0.97
CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol (2010) 0.94
Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res (2003) 0.91
Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res (1997) 0.88
Light-microscopic demonstration of methylene blue accumulation sites in mouse brain after supravital staining. Acta Anat (Basel) (1992) 0.87
Toxic metabolic encephalopathy after parathyroidectomy with methylene blue localization. Otolaryngol Head Neck Surg (2006) 0.86
Real-time, spatially resolved analysis of serotonin transporter activity and regulation using the fluorescent substrate, ASP+. J Neurochem (2010) 0.86
The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. J Neurochem (2009) 0.85
Methylene blue is a potent monoamine oxidase inhibitor. Can J Anaesth (2008) 0.83
Molecular microfluorometry: converting arbitrary fluorescence units into absolute molecular concentrations to study binding kinetics and stoichiometry in transporters. Handb Exp Pharmacol (2006) 0.80
Methylene blue and serotonin toxicity: definite causal link. Psychosomatics (2010) 0.79
Comparison of preoperative imaging techniques (thallium technetium scan and ultrasonography) and intraoperative staining (with methylene blue) in localizing the parathyroid glands. Radiol Med (1995) 0.77
Shift from goal-directed to habitual cocaine seeking after prolonged experience in rats. J Neurosci (2010) 2.33
Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci U S A (2006) 2.29
D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol (2007) 2.28
PI 3-kinase regulation of dopamine uptake. J Neurochem (2002) 1.64
Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci (2003) 1.63
Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun (2002) 1.49
Neural systems underlying opiate addiction. J Neurosci (2002) 1.33
Regulation of monoamine transporters: Role of transporter phosphorylation. Pharmacol Ther (2010) 1.30
Methylene blue and Alzheimer's disease. Biochem Pharmacol (2009) 1.27
Cellular and molecular actions of Methylene Blue in the nervous system. Med Res Rev (2011) 1.22
Repeated ethanol intoxication induces behavioral sensitization in the absence of a sensitized accumbens dopamine response in C57BL/6J and DBA/2J mice. Neuropsychopharmacology (2006) 1.21
Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB J (2011) 1.19
Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem (2007) 1.19
Pathobiology of dynorphins in trauma and disease. Front Biosci (2005) 1.17
Enhanced responsiveness to novelty and cocaine is associated with decreased basal dopamine uptake and release in the nucleus accumbens: quantitative microdialysis in rats under transient conditions. J Neurosci (2003) 1.08
Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol (2010) 1.08
Behavioural sensitization and enhanced dopamine response in the nucleus accumbens after intravenous cocaine self-administration in mice. Eur J Neurosci (2003) 1.07
Quantitative no-net-flux microdialysis permits detection of increases and decreases in dopamine uptake in mouse nucleus accumbens. J Neurosci Methods (2006) 1.05
Overview of brain microdialysis. Curr Protoc Neurosci (2009) 1.05
Proliferation and apoptosis in the developing human neocortex. Anat Rec (2002) 1.05
Kappa-opioid receptor modulation of accumbal dopamine concentration during operant ethanol self-administration. Neuropharmacology (2006) 1.04
Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion. Neuropsychopharmacology (2013) 1.04
Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology (Berl) (2008) 1.03
Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry (2004) 1.00
Selective impairment of GABAergic synaptic transmission in the flurothyl model of neonatal seizures. Eur J Neurosci (2006) 1.00
The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. Neuropsychopharmacology (2007) 0.99
Nkx6.1 controls migration and axon pathfinding of cranial branchio-motoneurons. Development (2003) 0.99
Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion. Neuropsychopharmacology (2013) 0.99
Recurrent neonatal seizures result in long-term increases in neuronal network excitability in the rat neocortex. Eur J Neurosci (2010) 0.98
Endogenous kappa opioid receptor systems modulate the responsiveness of mesoaccumbal dopamine neurons to ethanol. Alcohol Clin Exp Res (2006) 0.96
The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther (2010) 0.96
Basal and morphine-evoked dopaminergic neurotransmission in the nucleus accumbens of MOR- and DOR-knockout mice. Eur J Neurosci (2003) 0.95
Drug-induced GABA transporter currents enhance GABA release to induce opioid withdrawal behaviors. Nat Neurosci (2011) 0.93
Nucleus accumbens-derived glial cell line-derived neurotrophic factor is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system. J Neurosci (2010) 0.91
Long-term suppression of GABAergic activity by neonatal seizures in rat somatosensory cortex. Epilepsy Res (2009) 0.90
Postnatal changes in functional activities of the pig's brain: a combined functional magnetic resonance imaging and immunohistochemical study. Neurosignals (2005) 0.89
Alteration of synaptic plasticity by neonatal seizures in rat somatosensory cortex. Epilepsy Res (2013) 0.88
On the interaction of β-amyloid peptides and α7-nicotinic acetylcholine receptors in Alzheimer's disease. Curr Alzheimer Res (2013) 0.88
Role of extracellular Ca2+ in gating of CaV1.2 channels. J Physiol (2005) 0.88
Pharmacological and genetic manipulation of kappa opioid receptors: effects on cocaine- and pentylenetetrazol-induced convulsions and seizure kindling. Neuropharmacology (2006) 0.88
Real-time, spatially resolved analysis of serotonin transporter activity and regulation using the fluorescent substrate, ASP+. J Neurochem (2010) 0.86
Cholinergic stimulation of the immune system protects against lethal infection by Salmonella enterica serovar Typhimurium. Immunology (2010) 0.86
Blockade of endogenous neuraminidase leads to an increase of neuronal excitability and activity-dependent synaptogenesis in the rat hippocampus. Eur J Neurosci (2010) 0.85
The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. J Neurochem (2009) 0.85
Rab7 silencing prevents μ-opioid receptor lysosomal targeting and rescues opioid responsiveness to strengthen diabetic neuropathic pain therapy. Diabetes (2012) 0.84
Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neurosci Lett (2003) 0.84
Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neurosci Lett (2005) 0.84
Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci (2008) 0.84
The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes. J Pharmacol Exp Ther (2007) 0.83
Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. J Neural Transm (Vienna) (2009) 0.83
Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels. Neuropharmacology (2005) 0.82
Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. Brain Res (2009) 0.82
Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion. Neurochem Res (2009) 0.82
Basolateral amygdala-driven augmentation of medial prefrontal cortex GABAergic neurotransmission in response to environmental stimuli associated with cocaine administration. Neuropsychopharmacology (2011) 0.82
High concentrations of phenylalanine stimulate peroxisome proliferator-activated receptor gamma: implications for the pathophysiology of phenylketonuria. Neurobiol Dis (2008) 0.81
Cocaine up-regulation of the norepinephrine transporter requires threonine 30 phosphorylation by p38 mitogen-activated protein kinase. J Biol Chem (2011) 0.81
The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat. Psychopharmacology (Berl) (2010) 0.79
Thrombin facilitates seizures through activation of persistent sodium current. Ann Neurol (2012) 0.79
The pattern of c-fos activation in the CNS is related to behavior in the mudskipper, Periophthalmus cantonensis. Behav Brain Res (2005) 0.79
Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon. J Appl Toxicol (2012) 0.78
Tyrosine phosphorylation of the human serotonin transporter: a role in the transporter stability and function. Mol Pharmacol (2011) 0.78
Cholecystokinin B-type receptors mediate a G-protein-dependent depolarizing action of sulphated cholecystokinin ocatapeptide (CCK-8s) on rodent neonatal spinal ventral horn neurons. J Neurophysiol (2007) 0.78
The effects of anandamide transport inhibitor AM404 on voltage-dependent calcium channels. Eur J Pharmacol (2010) 0.78
Effects of phenothiazine-class antipsychotics on the function of α7-nicotinic acetylcholine receptors. Eur J Pharmacol (2011) 0.78
Effects of cannabidiol on the function of α7-nicotinic acetylcholine receptors. Eur J Pharmacol (2013) 0.78
Profiles of serotonin receptors in the developing human thalamus. Psychiatry Res (2010) 0.77
Alleviation of neuropathic pain hypersensitivity by inhibiting neuronal pentraxin 1 in the rostral ventromedial medulla. J Neurosci (2012) 0.77
Effects of cocaine-kindling on the expression of NMDA receptors and glutamate levels in mouse brain. Neurochem Res (2010) 0.77
Microdialysis in rodents. Curr Protoc Neurosci (2009) 0.77
Caspase-3 immunoreactivity in different cortical areas of young and aging macaque (Macaca mulatta) monkeys. Neurosignals (2006) 0.77
Effect of neuraminidase treatment on persistent epileptiform activity in the rat hippocampus. Pharmacol Rep (2011) 0.77
CT-guided blocks and neuroablation of the ganglion impar (Walther) in perineal pain: anatomy, technique, safety, and efficacy. Clin J Pain (2009) 0.77
Age-related alterations in cytochrome c-mediated caspase activation in rhesus macaque monkey (Macaca mulatta) brains. Brain Res Mol Brain Res (2004) 0.76
Methylene blue inhibits the function of α7-nicotinic acetylcholine receptors. CNS Neurol Disord Drug Targets (2012) 0.76
Worldwide decline of sturgeons. Science (2005) 0.75
Electrolyte therapy reduces spike-and-wave discharges in the WAG/Rij rat model of absence epilepsy. Epilepsy Behav (2012) 0.75
Pralidoxime hydrolysis of thiocholine esters. Vet Hum Toxicol (2003) 0.75
Detection and quantification of neurotransmitters in dialysates. Curr Protoc Neurosci (2009) 0.75
N3,N7-diaminophenothiazinium derivatives as antagonists of α7-nicotinic acetylcholine receptors expressed in Xenopus oocytes. Pharmacol Res (2012) 0.75
Sub-chronic exposure to paraoxon neither induces nor exacerbates diabetes mellitus in Wistar rat. J Appl Toxicol (2012) 0.75
Alloxan reduces amplitude of ventricular myocyte shortening and intracellular Ca2+ without altering L-type Ca2+ current, sarcoplasmic reticulum Ca2+ content or myofilament sensitivity to Ca2+ in Wistar rats. Mol Cell Biochem (2010) 0.75
Medicinal chemistry of drugs with active metabolites following conjugation. Mini Rev Med Chem (2013) 0.75
Reversible cholinesterase inhibitors as pre-treatment for exposure to organophosphates: assessment using azinphos-methyl. J Appl Toxicol (2014) 0.75
A trivalent approach for determining in vitro toxicology: Examination of oxime K027. J Appl Toxicol (2014) 0.75
Analysis of pralidoxime in serum, brain and CSF of rats. Med Chem (2009) 0.75